Outcome of Bowel Resection in Women with Advanced Ovarian Carcinoma

被引：2

作者：

Sebastian A. ^{[1
]}

Thomas A. ^{[1
]}

Varghese G. ^{[2
]}

Yadav B. ^{[3
]}

Chandy R. ^{[1
]}

Peedicayil A. ^{[1
]}

机构：

[1] Department of Gynaecologic Oncology, CMC Hospital, Vellore

[2] Department of Colorectal Surgery, CMC Hospital, Vellore

[3] Department of Biostatistics, CMC Hospital, Vellore

来源：

Indian Journal of Surgical Oncology | 2018年 / 9卷 / 4期

关键词：

Bowel resection; Ovarian cancer;

D O I：

10.1007/s13193-018-0790-2

中图分类号：

学科分类号：

摘要：

To evaluate the mortality and morbidity related to bowel resection in women with advanced ovarian carcinoma. Retrospective case series of 47 women with stage III and IV carcinoma ovary who underwent bowel resection, over the period of 5 years from Jan 2011 to Dec 2015. The risk factors for perioperative morbidity and death were determined by regression analysis. The disease free and overall survival were determined by Kaplan-Meier plots. In this cohort, 64% (30/47) had primary debulking, 21% (10/47) had interval debulking, and 15% (7/47) had secondary debulking. The mean period of follow-up was 23 months (1 to 45 months). There were no anastomotic leaks. The commonest morbidities were relaparotomy (8.5%), surgical site infection (12%), and paralytic ileus (19%). The overall morbidity was 42.6% (20/47). The 30-day mortality was 4.2% (2/47). The recurrence rate was 51% (20/47). The overall mortality from ovarian cancer in this cohort was 40% (19/47) during the follow-up period. Stage and histology seemed to be important risk factors for morbidity. Low BMI and sub-optimal debulking were significant risk factors for recurrence and death in univariate analysis. Bowel resection, in optimally selected cases of advanced carcinoma ovary, is often required for optimal cytoreduction. It carries a reasonable peri-operative mortality and morbidity and improves overall survival. © 2018, Indian Association of Surgical Oncology.

引用

页码：511 / 518

页数：7

共 39 条

[1]

Heintz A.P., Odicino F., Maisonneuve P., Beller U., Benedet J.L., Creasman W.T., Et al., Carcinoma of the ovary, Int J Gynecol Obstet, 83, pp. 135-166, (2003)

[2]

Pecorelli S., Favalli G., Zigliani L., Odicino F., Cancer in women, Int J Gynecol Obstet, 82, pp. 369-379, (2003)

[3]

Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., Mannel R.S., DeGeest K., Hartenbach E.M., Baergen R., Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study, J Clin Oncol, 21, pp. 3194-3200, (2003)

[4]

Siegel R., Ward E., Brawley O., Jemal A., Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths, CA Cancer J Clin, 61, pp. 212-236, (2011)

[5]

Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., Copeland L.J., Walker J.L., Burger R.A., Intraperitoneal cisplatin and paclitaxel in ovarian cancer, N Engl J Med, 354, pp. 34-43, (2006)

[6]

Bristow R.E., Montz F.J., Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator, Gynecol Oncol, 83, pp. 39-48, (2001)

[7]

Eisenkop S.M., Friedman R.L., Wang H.J., Complete cytoreductive surgery is feasible and maximizessurvival in patients with advanced epithelial ovarian cancer: a prospective study, Gynecol Oncol, 69, pp. 103-108, (1998)

[8]

Eisenkop S.M., Spirtos N.M., Friedman R.L., Lin W.C., Pisani A.L., Perticucci S., Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study, Gynecol Oncol, 90, pp. 390-396, (2003)

[9]

Le T., Krepart G.V., Lotocki R.J., Heywood M.S., Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?, Gynecol Oncol, 67, pp. 208-214, (1997)

[10]

Makar A.P., Baekelandt M., Trope C.G., Kristensen G.B., The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer, Gynecol Oncol, 56, pp. 175-180, (1995)

← 1 2 3 4 →